MCID: LVR013
MIFTS: 71

Liver Disease

Categories: Blood diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Liver Disease

MalaCards integrated aliases for Liver Disease:

Name: Liver Disease 12 15 38 17
Liver Diseases 55 43 44 72
Liver Dysfunction 55 72
Liver Failure 55 72
Abnormality of the Liver 29
Disorder of Liver 12
Hepatic Disorder 12
Hepatic Failure 29
Hepatic Disease 15

Classifications:



External Ids:

Disease Ontology 12 DOID:409
ICD9CM 35 573.9
MeSH 44 D008107
NCIt 50 C3196
SNOMED-CT 68 62857009
UMLS 72 C0023895 C0085605 C0086565

Summaries for Liver Disease

MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. There are many kinds of liver diseases: Diseases caused by viruses, such as hepatitis A, hepatitis B, and hepatitis C Diseases caused by drugs, poisons, or too much alcohol. Examples include fatty liver disease and cirrhosis. Liver cancer Inherited diseases, such as hemochromatosis and Wilson disease Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. Sometimes there are no symptoms. Tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

MalaCards based summary : Liver Disease, also known as liver diseases, is related to fatty liver disease and polycystic liver disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Disease is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Metabolism and Selenium Micronutrient Network. The drugs Prednisolone phosphate and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 75 Liver disease (also called hepatic disease) is a type of damage to or disease of the liver. Whenever the... more...

Related Diseases for Liver Disease

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Acute Liver Failure

Diseases related to Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1879)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 35.5 TNF PNPLA3 INS CYP2E1 ADIPOQ
2 polycystic liver disease 35.4 PRKCSH PKHD1 PKD1 GANAB ALB
3 polycystic liver disease 1 with or without kidney cysts 35.3 PRKCSH PKHD1 PKD1
4 fatty liver disease, nonalcoholic 1 35.2 KRT18 INS GPT ADIPOQ
5 polycystic kidney disease 2 with or without polycystic liver disease 35.1 PRKCSH PKHD1 PKD1 GANAB
6 polycystic kidney disease 4 with or without polycystic liver disease 35.1 PRKCSH PKHD1 PKD1
7 polycystic kidney disease 1 with or without polycystic liver disease 35.0 PRKCSH PKHD1 PKD1
8 alcoholic hepatitis 34.1 TNF KRT18 GPT F2 CYP2E1 ALB
9 wilson disease 33.6 GPT F2 ALB
10 cholangitis, primary sclerosing 33.4 GPT DLAT ALB ABCB4
11 acute liver failure 33.3 GPT F2 ALB
12 sclerosing cholangitis 33.3 TNF ALB ABCB4 ABCB11
13 hepatic encephalopathy 33.3 TNF GPT F2 ALB
14 autoimmune hepatitis 33.0 GPT F2 DLAT
15 congenital hepatic fibrosis 32.9 PKHD1 PKD1
16 cholestasis, progressive familial intrahepatic, 4 32.9 ABCB4 ABCB11
17 alcoholic liver cirrhosis 32.7 PNPLA3 F2 CYP2E1 ALB
18 liver cirrhosis 32.6 SERPINA1 MEG3 KRT18 GPT F2 CYP2E1
19 hepatitis 32.5 TNF KRT18 GPT F2
20 portal hypertension 32.5 TNF PKHD1 GPT F2 ALB
21 hepatic coma 32.4 GPT F2 ALB
22 viral hepatitis 32.4 TNF SERPINA1 KRT18 GPT F2 ALB
23 cholestasis 32.4 HSD3B7 GPT F2 ABCB4 ABCB11
24 hepatitis b 32.3 TNF GPT F2 ALB
25 cryptogenic cirrhosis 32.3 KRT18 F2
26 polycystic kidney disease 32.3 PRKCSH PKHD1 PKD1 GANAB
27 hepatitis a 32.1 TNF SERPINA1 GPT F2 ALB
28 cholangitis 32.1 TNF GPT F2 DLAT ALB ABCB4
29 peritonitis 32.0 TNF F2 ALB
30 kidney disease 32.0 PKHD1 PKD1 INS GANAB ALB ADIPOQ
31 autosomal dominant polycystic kidney disease 32.0 PKHD1 PKD1 GANAB ALB
32 atherosclerosis susceptibility 31.8 TNF INS ADIPOQ
33 sleep apnea 31.8 TNF INS ADIPOQ
34 obstructive jaundice 31.8 TNF GPT F2 ALB
35 bilirubin metabolic disorder 31.8 GPT F2 ALB
36 body mass index quantitative trait locus 11 31.8 TNF PNPLA3 INS GPT CYP2E1 ADIPOQ
37 hepatitis e 31.8 TNF GPT F2 ALB
38 proteasome-associated autoinflammatory syndrome 1 31.8 TNF INS ALB ADIPOQ
39 schistosomiasis 31.7 TNF F2 ALB
40 cholelithiasis 31.7 GPT ALB ABCB4
41 arteries, anomalies of 31.7 TNF INS ALB ADIPOQ
42 end stage renal failure 31.6 TNF PKD1 ALB
43 inherited metabolic disorder 31.5 SERPINA1 PNPLA3 INS ADIPOQ
44 overnutrition 31.5 TNF INS ADIPOQ
45 protein-energy malnutrition 31.4 TNF GPT ALB
46 vascular disease 31.4 TNF INS F2 ALB ADIPOQ
47 eclampsia 31.4 TNF F2 ALB
48 diabetes mellitus, noninsulin-dependent 31.4 TNF INS GPT ALB ADIPOQ
49 non-a-e hepatitis 31.3 F2 ALB
50 antipyrine metabolism 31.3 F2 ALB

Comorbidity relations with Liver Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Liver Disease:



Diseases related to Liver Disease

Symptoms & Phenotypes for Liver Disease

UMLS symptoms related to Liver Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas, digestive system symptom, liver tender, abnormal bruising

MGI Mouse Phenotypes related to Liver Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 ABCB11 ABCB4 ADIPOQ ALB CYP2E1 F2
2 growth/size/body region MP:0005378 10.11 ABCB11 ABCB4 ADIPOQ F2 FAH HSD3B7
3 liver/biliary system MP:0005370 10.1 ABCB11 ABCB4 ADIPOQ ALB CYP2E1 FAH
4 digestive/alimentary MP:0005381 10.01 ABCB4 ALB F2 HSD3B7 INS PKD1
5 mortality/aging MP:0010768 9.97 ABCB11 ADIPOQ ALB CYP2E1 F2 FAH
6 neoplasm MP:0002006 9.5 ABCB4 ADIPOQ ALB CYP2E1 FAH PKD1
7 renal/urinary system MP:0005367 9.17 ADIPOQ ALB FAH INS PKD1 PKHD1

Drugs & Therapeutics for Liver Disease

Drugs for Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1098)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5
Dalteparin Approved Phase 4 9005-49-6
6
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
8
Azithromycin Approved Phase 4 83905-01-5 447043 55185
9
Liraglutide Approved Phase 4 204656-20-2 44147092
10
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
11
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
12
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
13
Vancomycin Approved Phase 4 1404-90-6 441141 14969
14
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
15
Insulin Lispro Approved Phase 4 133107-64-9
16
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
17
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
18
Insulin glulisine Approved Phase 4 207748-29-6
19
Lixisenatide Approved Phase 4 320367-13-3
20
Arsenic trioxide Approved, Investigational Phase 4 1327-53-3 518740
21
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
22
Atenolol Approved Phase 4 29122-68-7 2249
23
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
24
Cefoxitin Approved Phase 4 35607-66-0 441199
25
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
26
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
27
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
28
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
29
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
30
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
31
Ethanolamine oleate Approved Phase 4 2272-11-9
32
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
33
Pravastatin Approved Phase 4 81093-37-0 54687
34
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
35
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
36
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
37
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
38
Baclofen Approved Phase 4 1134-47-0 2284
39
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
40
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
41
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
42
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
43
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
44
Deferiprone Approved Phase 4 30652-11-0 2972
45
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
46
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
47
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
48
Simvastatin Approved Phase 4 79902-63-9 54454
49
Norfloxacin Approved Phase 4 70458-96-7 4539
50
Gliclazide Approved Phase 4 21187-98-4 3475

Interventional clinical trials:

(show top 50) (show all 3709)
# Name Status NCT ID Phase Drugs
1 Granulocyte Colony-stimulating Factor(G-CSF) in the Treatment of Hepatic Failure: a Prospective Randomized Controlled Clinical Study Unknown status NCT02331745 Phase 4 Granulocyte colony-stimulating factor;standard treatment
2 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
3 Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease Unknown status NCT02366845 Phase 4
4 Randomised Controlled Study Comparing Use of Popofol Plus Fentanyl Versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients With Advanced Liver Disease. Unknown status NCT03063866 Phase 4 Propofol;Midazolam;Fentanyl
5 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
6 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
7 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
8 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study Unknown status NCT02837302 Phase 4 Livact
9 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
10 Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion From Tacrolimus (Bid) to Advagraf® (qd) in Stable Liver Transplant Recipients Unknown status NCT02882113 Phase 4 Advagraf
11 A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
12 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
13 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
14 Hepatic Function and Bile Acid in Preterm Infants Receiving Parenteral Lipids Emulsion Unknown status NCT01786759 Phase 4 ClinOleic;Intralipid
15 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
16 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
17 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
18 Intravenous Paracetamol Versus Intravenous Dexketoprofen in Patients Presented With Dysmenorrhea in Emergency Department Unknown status NCT02373514 Phase 4 Paracetamol;Dexketoprofen
19 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
20 A Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Intra-articular Catheter (IAC) Following Primary Total Knee Arthroplasty Unknown status NCT02497911 Phase 4 Ropivicaine;Bupivicaine
21 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
22 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
23 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme, a Randomised Controlled Trial Unknown status NCT01429779 Phase 4 Movicol
24 The Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
25 A Study Comparing Thymoglobulin to Tacrolimus in Liver Transplant and Impact on Renal Function Unknown status NCT00564538 Phase 4 anti-thymocyte globulin (rabbit);tacrolimus
26 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
27 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
28 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
29 Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
30 A Double-Blinded Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Local Infiltration of Analgesia (LIA) Following Primary Total Knee Arthroplasty Unknown status NCT02603900 Phase 4 ropivacaine;bupivacaine
31 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
32 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
33 Efficacy and Safety of Certican® in Combination With Myfortic® in Adult Renal Allograft Recipients Following Calcineurin Inhibitor Withdrawal at Week 16 Compared to Patients Who Are Maintained on Tacrolimus and Myfortic® Unknown status NCT01399242 Phase 4 Certican
34 The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Unknown status NCT02501850 Phase 4 Liraglutide;metformin
35 A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis Unknown status NCT00761098 Phase 4 Standard Care;Experimental
36 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
37 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
38 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (Viread(R)) in Preventing Hepatocellular Carcinoma Recurrence in Chronic Hepatitis B Virus Infected Patients With Low Viral Load at Baseline Treated With Radiofrequency Ablation or Resection Unknown status NCT02308319 Phase 4 Tenofovir disoproxil fumarate
39 An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
40 the Safety and Effect in TB Patients With NAC Unknown status NCT02889757 Phase 4 Acteylcysteine
41 Treating HIV-infected Elite Controllers as a Model of HIV Remission Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
42 RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
43 Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
44 Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study) Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
45 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
46 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study Unknown status NCT00845936 Phase 4 Metformin
47 the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy Unknown status NCT03230851 Phase 4 aspirin 100mg/d therapy;aspirin 100mg/2d therapy;aspirin 100mg/3d therapy;aspirin 50mg bid therapy;aspirin 75mg/d therapy;aspirin 50mg/d therapy;indobufen 100mg bid therapy
48 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
49 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
50 Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin

Search NIH Clinical Center for Liver Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


alglucerase
Gadoxetic acid
imiglucerase
Medium chain triglycerides

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: liver diseases

Genetic Tests for Liver Disease

Genetic tests related to Liver Disease:

# Genetic test Affiliating Genes
1 Hepatic Failure 29
2 Abnormality of the Liver 29

Anatomical Context for Liver Disease

MalaCards organs/tissues related to Liver Disease:

41
Liver, Testes, Kidney, Bone, T Cells, Endothelial, Heart

Publications for Liver Disease

Articles related to Liver Disease:

(show top 50) (show all 49409)
# Title Authors PMID Year
1
Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease. 38 17
31393374 2019
2
von Willebrand Factor: A Tool to Predict Severity and Prognosis in Liver Disease. 38 17
31324089 2018
3
Serum metabolome and targeted bile acid profiling reveals potential novel biomarkers for drug-induced liver injury. 17
31374067 2019
4
Elevated hydroxyacylcarnitines in a carrier of LCHAD deficiency during acute liver disease of pregnancy - a common feature of the pregnancy complication? 9 38
20363656 2010
5
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. 9 38
20371660 2010
6
The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. 9 38
20415685 2010
7
The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. 9 38
20422496 2010
8
The PXR is a drug target for chronic inflammatory liver disease. 9 38
20416375 2010
9
Beneficial effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver disease in high-fat fed C57BL/6 mice. 9 38
20490434 2010
10
Negative correlation between neuropeptide Y/agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy. 9 38
19942238 2010
11
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. 9 38
20102716 2010
12
Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study. 9 38
20503453 2010
13
Hepatic expression of thyroid hormone-responsive spot 14 protein is regulated by constitutive androstane receptor (NR1I3). 9 38
20185760 2010
14
Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. 9 38
20200515 2010
15
Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. 9 38
19946731 2010
16
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. 9 38
19881359 2010
17
Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. 9 38
20473736 2010
18
An International Sensitivity Index (ISI) derived from patients with abnormal liver function improves agreement between INRs determined with different reagents. 9 38
20174759 2010
19
[The value of MELD in the allocation of priority for liver transplantation candidates]. 9 38
19631411 2010
20
Studies of gamma-glutamyl transferase in alpha-1 antitrypsin deficiency. 9 38
20397813 2010
21
Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease? 9 38
20406065 2010
22
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. 9 38
20335584 2010
23
The new therapeutic frontier--nuclear receptors and the liver. 9 38
20133000 2010
24
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. 9 38
20150538 2010
25
Natural anticoagulants can be useful predictors of severity in chronic liver disease. 9 38
20019598 2010
26
The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. 9 38
20093562 2010
27
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. 9 38
19931264 2010
28
Nonlinear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis. 9 38
19770674 2010
29
Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. 9 38
19817962 2010
30
[The roles of cyclooxygenase-2 and 5-lipoxygenase in liver disease]. 9 38
20196963 2010
31
Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. 9 38
20170533 2010
32
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. 9 38
20176643 2010
33
Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. 9 38
19829123 2010
34
[Patomechanisms of hepatic steatosis]. 9 38
20159747 2010
35
Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. 9 38
19793164 2010
36
The role of cytokines in non-alcoholic fatty liver disease. 9 38
20460908 2010
37
Tumor necrosis factor-alpha accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease. 9 38
20043871 2010
38
Differential diagnosis of liver diseases using serum biomarkers. 9 38
20414942 2010
39
[Is venous thrombembolism during pregnancy an indication for routine assay of antithrombin activity and antithrombin supplementation?]. 9 38
20232702 2010
40
Plasma interleukin-18/interleukin-18 binding protein ratio in Chinese with NAFLD. 9 38
20422882 2010
41
Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. 9 38
20040336 2010
42
The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. 9 38
19940802 2010
43
Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis. 9 38
19330428 2010
44
Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. 9 38
19910932 2010
45
Apoptosis in immune-mediated liver diseases. 9 38
20460903 2010
46
Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. 9 38
19950230 2010
47
Animal models for hepatitis C and related liver disease. 9 38
20156300 2010
48
Dephosphorylation of threonine 38 is required for nuclear translocation and activation of human xenobiotic receptor CAR (NR1I3). 9 38
19858220 2009
49
[Fatty liver disease, insulin resistance and adiponectin in an obese pediatric population]. 9 38
19850541 2009
50
Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. 9 38
19769633 2009